Suchen
Alterity Therapeutics Ltd
ATHEZur Watchlist hinzufügen
3.960USD
+0.410+11.55%
Trading geöffnet 09/24, 09:42（ET）
72.11MMarktkapitalisierung
VerlustKGV TTM
Über Alterity Therapeutics Ltd Unternehmen
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase II clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.
Alterity Therapeutics Ltd Profil
BörsenkürzelATHE
Name des UnternehmensAlterity Therapeutics Ltd
IPO-datumMar 28, 2000
CEOStamler (David A)
Anzahl der mitarbeiter9
WertpapierartDepository Receipt
GeschäftsjahresendeMar 28
AddresseLevel 14, 350 Collins Street
StadtMELBOURNE
BörseNASDAQ OMX - NASDAQ BASIC
LandAustralia
Postleitzahl3000
Telefon61393494906
Websitehttps://alteritytherapeutics.com/
BörsenkürzelATHE
IPO-datumMar 28, 2000
CEOStamler (David A)
Führungskräfte von Alterity Therapeutics Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Dr. David A. Stamler, M.D.
Dr. David A. Stamler, M.D.
Chief Executive Officer, Managing Director, Executive Director
Chief Executive Officer, Managing Director, Executive Director
--
--
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Julian Barbaczy
Mr. Julian Barbaczy
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Ann Michelle Cunningham
Ms. Ann Michelle Cunningham
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Dr. David A. Stamler, M.D.
Dr. David A. Stamler, M.D.
Chief Executive Officer, Managing Director
Chief Executive Officer, Managing Director
--
--
Ms. Hannah Howlett
Ms. Hannah Howlett
Investor Relations
Investor Relations
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Peter Ashley Marks
Mr. Peter Ashley Marks
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Lawrence B. Gozlan
Mr. Lawrence B. Gozlan
Non-Executive Director
Non-Executive Director
--
--
Dr. David A. Stamler, M.D.
Dr. David A. Stamler, M.D.
Chief Executive Officer, Managing Director, Executive Director
Chief Executive Officer, Managing Director, Executive Director
--
--
Ms. Abby Macnish Niven
Ms. Abby Macnish Niven
Chief Financial Officer, Company Secretary
Chief Financial Officer, Company Secretary
--
--
Mr. Julian Barbaczy
Mr. Julian Barbaczy
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Ann Michelle Cunningham
Ms. Ann Michelle Cunningham
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Alterity Therapeutics Ltd?
Die fünf größten Anteilseigner von Alterity Therapeutics Ltd sind: Mr. Peter Ashley Marks
Wie viele Institutionen halten Anteile an Alterity Therapeutics Ltd (ATHE)?
Mit Stand vom 2026Q1 halten 32 Institutionen Anteile an Alterity Therapeutics Ltd, mit einem Gesamtmarktwert von etwa 327.31K, was 1.81% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -185355.00 gestiegen.